Johnson & Johnson Reports Tremfya Sales Growth of 68.2% in 3Q
Tremfya worldwide operational sales reached $2.4 billion, up 68.2% in the third quarter, helping cushion Stelara sales erosion.
Johnson & Johnson's Tremfya is emerging as a key growth driver in immunology as biosimilar competition erodes Stelara sales. 4 billion. That growth helped cushion the blow from Stelara, which saw worldwide sales drop 54…